In this episode of UroNurse, hosted by Vic Senese, RN, BSN, FAUNA, we explore how treatment for urothelial carcinoma and muscle-invasive bladder cancer (MIBC) is rapidly evolving.

Traditional platinum-based chemotherapy has long been the cornerstone of treatment, but a paradigm shift is underway. With the emergence of immune checkpoint inhibitors, antibody-drug conjugates, and combination regimens, the first-line approach to locally advanced and metastatic bladder cancer is being redefined.

We’ll review the latest clinical trial data, discuss patient selection for new combination therapies, and highlight what these innovations mean for urology nurses, oncology providers, and patients navigating advanced bladder cancer treatment.

Stay ahead of the curve as Vic explains the science, strategy, and nursing implications behind this transformation in bladder cancer care.

🔔 Subscribe to my channel for more urologic updates, news, and education:
👉 https://www.youtube.com/@UroNurse1

The expert's opinions in this communication are personal and not representative of any organization. They are for informational purposes only, not official guidance. Viewers are advised to use their judgment, seek additional advice, and take responsibility for any actions based on these opinions.

(Audio) Changing the Paradigm of First-Line Therapy for Locally Advanced/Metastatic Urothelial Carcinoma and Muscle-Invasive Bladder Cancer

UroNurse